<div id="readability-page-1"><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/johnson--johnson-logo-1200x675.png/query-dj0yMDIyMTAyMDEzNTkyMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/johnson--johnson-logo-1200x675.png/query-dj0yMDIyMTAyMDEzNTkyMw"/>Fiera Capital Corp lowered its holdings in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,269,383 shares of the company's stock after selling 360,532 shares during the period. Johnson &amp; Johnson comprises 2.1% of Fiera Capital Corp's portfolio, making the stock its 13th largest position. Fiera Capital Corp owned 0.18% of Johnson &amp; Johnson worth $669,183,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report</li></ul><p>Other hedge funds have also recently bought and sold shares of the company. Pathway Financial Advisors LLC raised its holdings in Johnson &amp; Johnson by 4.3% in the fourth quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company's stock valued at $852,000 after acquiring an additional 226 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of Johnson &amp; Johnson by 5.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company's stock worth $46,685,000 after purchasing an additional 15,490 shares during the last quarter. OneAscent Financial Services LLC lifted its position in shares of Johnson &amp; Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company's stock worth $1,542,000 after purchasing an additional 4,457 shares during the last quarter. Vestmark Advisory Solutions Inc. grew its stake in Johnson &amp; Johnson by 12.7% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company's stock worth $3,070,000 after purchasing an additional 2,201 shares in the last quarter. Finally, TrueMark Investments LLC bought a new stake in Johnson &amp; Johnson in the fourth quarter valued at about $1,458,000. Institutional investors and hedge funds own 69.55% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>Several analysts have weighed in on the stock. HSBC upgraded shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and set a $175.00 price objective on shares of Johnson &amp; Johnson in a research note on Thursday. StockNews.com upgraded Johnson &amp; Johnson from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 6th. Morgan Stanley dropped their price target on Johnson &amp; Johnson from $168.00 to $167.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Wednesday, April 17th. Finally, Bank of America lowered their price objective on Johnson &amp; Johnson from $180.00 to $170.00 and set a &#34;neutral&#34; rating for the company in a research note on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $175.86.</p><ul><li>3 Stocks Mega Investors Are Buying</li></ul><p><b>Get Our Latest Stock Analysis on JNJ</b></p><h2>Johnson &amp; Johnson Price Performance</h2><p>NYSE JNJ opened at $154.64 on Friday. The firm has a market capitalization of $372.17 billion, a PE ratio of 9.64, a P/E/G ratio of 2.55 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson &amp; Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company's 50 day simple moving average is $152.31 and its 200 day simple moving average is $155.07. </p><ul><li>MarketBeat Week in Review – 4/15 - 4/19</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts' consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson &amp; Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company's quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.68 EPS. As a group, equities research analysts forecast that Johnson &amp; Johnson will post 10.64 EPS for the current fiscal year. </p><h2>Johnson &amp; Johnson Increases Dividend</h2><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.21%. This is a boost from Johnson &amp; Johnson's previous quarterly dividend of $1.19. Johnson &amp; Johnson's dividend payout ratio is currently 29.68%. </p><h2>Johnson &amp; Johnson Company Profile</h2> (Free Report)<p>Johnson &amp; Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>What is a Dividend King? </li><li>MarketBeat Week in Review – 5/13 - 5/17</li><li>What to Know About Investing in Penny Stocks</li><li>Take-Two Interactive Software Offers 2nd Chance for Investors</li><li>5 discounted opportunities for dividend growth investors</li><li>Deere &amp; Company’s Q2 Report: Strong Revenue, Cautious Outlook </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Elon’s New Device is About to Shock the World <span><span><span>(From InvestorPlace)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NjY3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NjY3"/></span></p><h2>Should you invest $1,000 in Johnson &amp; Johnson right now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

600662

<p>Fiera Capital Corp reduced its holdings in Johnson & Johnson by 7.8% in the fourth quarter, according to its recent SEC filing. The fund owned 4,269,383 shares of the company's stock, making it the 13th largest position. Other hedge funds also bought and sold shares of the company. Several analysts have weighed in on the stock, with an average rating of "Moderate Buy" and a consensus target price of $175.86. Johnson & Johnson last posted its quarterly earnings data, reporting $2.71 EPS for the quarter. The company's quarterly revenue was up 2.3% compared to the same quarter last year.</p>

Fiera Capital Corp Reduces Position in Johnson & Johnson (NYSE:JNJ)